Acute pulmonary embolism treated with tissue plasminogen activator
- PMID: 2876327
- DOI: 10.1016/s0140-6736(86)90411-3
Acute pulmonary embolism treated with tissue plasminogen activator
Abstract
Recombinant human tissue-type plasminogen activator (rt-PA) was given via a peripheral vein to 36 patients with angiographically documented pulmonary embolism. The regimen was 50 mg/2 h followed by repeat angiography and, if necessary, an additional 40 mg/4 h. By 6 h, 34 of 36 patients had angiographic evidence of clot lysis, slight in 4, moderate in 6, and marked in 24. The quantitative score improved 21% by 2 h and 49% by 6 h. Fibrinogen decreased 30% from baseline at 2 h and 38% from baseline at 6 h. 2 patients had major complications: in one, bleeding from a pelvic tumour required surgery; in the other, who had had coronary artery bypass surgery eight days earlier, pericardial tamponade developed. These initial results in selected patients make a case for expanded investigational use of peripheral intravenous rt-PA in pulmonary embolism.
Similar articles
-
Thrombolytic therapy of acute pulmonary embolism: current status and future potential.J Am Coll Cardiol. 1987 Nov;10(5 Suppl B):96B-104B. doi: 10.1016/s0735-1097(87)80434-5. J Am Coll Cardiol. 1987. PMID: 3117862 Review.
-
Tissue plasminogen activator and acute pulmonary embolism.J Cell Biochem. 1988 Dec;38(4):303-12. doi: 10.1002/jcb.240380409. J Cell Biochem. 1988. PMID: 3149283
-
Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial.J Am Coll Cardiol. 1992 Jul;20(1):24-30. doi: 10.1016/0735-1097(92)90132-7. J Am Coll Cardiol. 1992. PMID: 1607532 Clinical Trial.
-
PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2.J Am Coll Cardiol. 1992 Sep;20(3):520-6. doi: 10.1016/0735-1097(92)90002-5. J Am Coll Cardiol. 1992. PMID: 1512328 Clinical Trial.
-
Tissue plasminogen activator.N Engl J Med. 1988 Oct 6;319(14):925-31. doi: 10.1056/NEJM198810063191407. N Engl J Med. 1988. PMID: 3138537 Review. No abstract available.
Cited by
-
Anticoagulants in venous thromboembolism.BMJ. 1988 Nov 19;297(6659):1285-8. doi: 10.1136/bmj.297.6659.1285. BMJ. 1988. PMID: 3144365 Free PMC article. Review. No abstract available.
-
Use of thrombolytic drugs in non-coronary disorders.Drugs. 1989 Nov;38(5):801-21. doi: 10.2165/00003495-198938050-00006. Drugs. 1989. PMID: 2689138 Review.
-
Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial.Chest. 2010 Feb;137(2):254-62. doi: 10.1378/chest.09-0765. Epub 2009 Sep 9. Chest. 2010. PMID: 19741062 Free PMC article. Clinical Trial.
-
Interventional therapies in acute pulmonary embolus-current trends and future directions.Br J Radiol. 2023 Sep;96(1149):20221151. doi: 10.1259/bjr.20221151. Epub 2023 Jul 14. Br J Radiol. 2023. PMID: 37449941 Free PMC article. Review.
-
Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.J Clin Invest. 1991 Mar;87(3):1082-90. doi: 10.1172/JCI115069. J Clin Invest. 1991. PMID: 1900308 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical